Compare stocks

Adocia SA is a clinical-stage biotechnology company headquartered in Lyon, France, specializing in the development of innovative formulations of therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Founded in 2005 by Gérard Soula and his sons Olivier and Rémi, the company has developed a proprietary BioChaperone® technology platform designed to enhance the efficacy and safety of therapeutic proteins. Adocia's clinical pipeline includes products such as BioChaperone Lispro, an ultra-rapid insulin formulation, and BioChaperone Combo, a combination of basal and rapid-acting insulins. The company has established a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize its products in China and other Asian and Middle Eastern territories. (,)

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.